Hi SF,

Ray Kausik is the chair of the BETonMACE steering committee, but he is not as such associated with RVX (or Zenith). He gave an excellent presentation at the investors day last year.

Jorge Plutzky has been heavily involved in investigations of JQ1, but I do not think he has anything to do with RVX208, but together with J. Bradner, he was corresponding author on a very important paper (Brown et al., 2014) that linked BET inhibitors with NFkB (=inflammation). We have not heard a lot about NFkB, but I am pretty sure we are soon going to. A link to the Brown et al. paper is found below.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224636/

John Kastelein has been involved in the phase 2 trials of RVX-208. He co-authored a rather negative paper on the results of ASSURE - not even mentioning the post hoc analysis! I wonder if he has somehow changed his mind - that would be pleasant news.

I don't think I have come across Stefano Del Prato in the context of RVX-208 or BET inhibitors.

Best,

B.